GALT Chief Medical Officer Khurram Jamil Buys $9.3K of Stock

Khurram Jamil, Chief Medical Officer at GALT, recently bought 7,557 shares of the company at an average price of $1.23, totaling $9,295.11. This transaction took place on June 23, 2026, and was not part of a pre-arranged trading plan.

Other Institutional Activity in GALT

Vanguard Capital Management LLC opened a new position in GALT, acquiring 1,966,542 shares valued at approximately $5,486,652. Meanwhile, Marshall Wace, LLP increased its holdings by 617,778 shares, bringing its total to 1,219,912 shares worth about $3,403,554, marking a 102.6% increase. Osaic Holdings, Inc. added 32,080 shares, ending with 1,122,670 shares valued at $3,132,240, a 2.9% increase. BlackRock, Inc. slightly boosted its stake by 2,679 shares to hold 799,237 shares, valued at around $2,229,871. Millennium Management LLC significantly increased its position by 562,926 shares, now holding 798,434 shares worth $2,227,631, reflecting a 239% increase.

Galectin Therapeutics Inc. Stock Up 6.4%

Shares of GALT traded near $4.14 on Friday. The stock has seen institutional interest with several funds increasing their stakes recently. While exact market cap and P/E information isn't available, the stock's recent price activity and analyst attention suggest ongoing interest.

Analysts Set New Price Targets

On June 23, 2026, HC Wainwright & Co. reiterated its 'buy' rating on GALT, maintaining a price target of $11. This firm has consistently supported GALT with a strong buy recommendation, reflecting confidence in the company's future prospects.

Insider Buying and Selling at Galectin Therapeutics Inc.

Khurram Jamil, Chief Medical Officer, engaged in multiple transactions. On June 23, 2026, he purchased 7,557 shares at $1.23 per share. Earlier, on May 26, 2026, he made another purchase of 568 shares at the same price. These transactions were not executed under a pre-planned trading agreement.

About GALT

GALT is a company involved in the biotechnology sector, focusing on developing therapies for fibrotic diseases. The company is headquartered in the United States and is actively engaged in research and development to advance its clinical programs.

Bottom Line

Khurram Jamil's recent purchase of GALT shares indicates his confidence in the company's direction. Institutional activity shows a mix of new entries and increased positions by major funds, suggesting broader interest. Analyst support remains strong, with HC Wainwright & Co. reiterating a 'buy' rating, pointing to optimism about GALT's future performance.